Published online May 12, 2020. doi: 10.4291/wjgp.v11.i3.57
Peer-review started: October 15, 2019
First decision: December 4, 2019
Revised: February 3, 2020
Accepted: March 1, 2020
Article in press: March 1, 2020
Published online: May 12, 2020
Processing time: 209 Days and 11.1 Hours
Core tip: Atherosclerosis and non-alcoholic fatty liver disease straddle a communal epidemiology, underlying mechanism and a clinical syndrome with protean manifestations, touching every organ in the body. Current therapeutic evidence supports the recommendation of addressing changes toward healthier lifestyles, including diet and physical exercise, in atherosclerosis and non-alcoholic fatty liver disease, even when defined only by non-invasive methodology. Pathway-based analysis are elucidating key molecular mechanisms underlying complex diseases addressing the joint effect and integrality as function unit of multiple genes, exploring large-scale “-omics” data. No element suggests, apart from naïve statistics, that one condition affects the other directly by any mechanism.
